Our findings lend further support to MMP12 as a pertinent therapeutic target for the prevention of clinical atherosclerosis and suggest that promoting galectin-3 expression may also represent an effective strategy to counter the actions of proinflammatory macrophages during plaque progression. The gene discussed is MMP12; the disease is atherosclerosis.